Skip to main content

Table 1 Baseline characteristics

From: Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study

Variable

Total (n = 5048)

Preoperative CA19-9 group

P value

Normal CA19-9 (n = 4310)

Elevated CA19-9 (n = 738)

Hospital, n (%)

   

 < 0.001

 YNCH

2170 (43.0)

1843 (42.8)

327 (44.3)

 

 KYU1

1111 (22.0)

986 (22.9)

125 (16.9)

 

 PUCH

604 (12.0)

541 (12.6)

63 (8.5)

 

 SYSU6

683 (13.5)

545 (12.6)

138 (18.7)

 

 CQU1

480 (9.5)

395 (9.2)

85 (11.5)

 

Male, n (%)

3029 (60.0)

2629 (61.0)

400 (54.2)

0.001

Agea

61.0 [51.0, 68.0]

61.0 [51.0, 68.0]

62.0 [51.0, 69.0]

0.114

Preoperative CEA, ng/ml a

3.8 [2.1, 9.4]

3.5 [2.0, 7.3]

10.6 [4.3, 28.1]

 < 0.001

Preoperative CEA group, n (%)

   

 < 0.001

 ≥ 5 ng/ml

2043 (40.5)

1519 (35.2)

524 (71.0)

 

 < 5 ng/ml

3005 (59.5)

2791 (64.8)

214 (29.0)

 

Preoperative CA19-9, U/ml a

11.9 [7.3, 23.4]

11.4 [6.4, 16.8]

69.7 [48.3, 143.5]

 < 0.001

Primary site, n (%)

   

 < 0.001

 Colon

2659 (52.7)

2216 (51.4)

443 (60.0)

 

 Rectum

2389 (47.3)

2094 (48.6)

295 (40.0)

 

Surgical approach, n (%)

   

0.079

 Laparoscopic resection

3010 (59.6)

2596 (60.2)

414 (56.1)

 

 Open resection

2035 (40.3)

1711 (39.7)

324 (43.9)

 

 Unknown

3 (0.1)

3 (0.1)

0 (0.0)

 

AJCC 8th ed. Stage, n (%)

    

 II

2724 (54.0)

2403 (55.8)

321 (43.5)

 < 0.001

 III

2324 (46.0)

1907 (44.2)

417 (56.5)

 

Lymph node yield, n (%)

   

0.216

 ≥ 12

3883 (76.9)

3305 (76.7)

578 (78.3)

 

 < 12

1163 (23.0)

1004 (23.3)

159 (21.5)

 

 Unknown

2 (0.0)

1 (0.0)

1 (0.1)

 

Tumor differentiation, n (%)

   

0.002

 Well-moderate

3533 (70.0)

3052 (70.8)

481 (65.2)

 

 Poor-undifferentiated

1040 (20.6)

853 (19.8)

187 (25.3)

 

 Unknown

475 (9.4)

405 (9.4)

70 (9.5)

 

Lymphovascular / Perineural invasion, n (%)

   

0.020

 Yes

1168 (23.1)

969 (22.5)

199 (27.0)

 

 No

3759 (74.5)

3240 (75.2)

519 (70.3)

 

 Unknown

121 (2.4)

101 (2.3)

20 (2.7)

 

MSI, n (%)

   

0.272

 Yes

886 (17.6)

751 (17.4)

135 (18.3)

 

 No

2354 (46.6)

2030 (47.1)

324 (43.9)

 

 Unknown

1808 (35.8)

1529 (35.5)

279 (37.8)

 

Adjuvant chemotherapy, n (%)

   

0.261

 Yes

3576 (70.8)

3035 (70.4)

541 (73.3)

 

 No

1471 (29.1)

1274 (29.6)

197 (26.7)

 

 Unknown

1 (0.0)

1 (0.0)

0 (0.0)

 

Mucinous (colloid) type, n (%)

   

 < 0.001

 Yes

395 (7.8)

303 (7.0)

92 (12.5)

 

 No

4648 (92.1)

4002 (92.9)

646 (87.5)

 

 Unknown

475 (9.4)

405 (9.4)

70 (9.5)

 
  1. Note: a Data is median [IQR]
  2. CA 19–9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, MSI microsatellite instability, CQU1 the First Affiliated Hospital of Chongqing Medical University, KMU1 the First Affiliated Hospital of Kunming Medical University, PUCH Peking University Cancer Hospital & Institute, SYSU6 the Sixth Affiliated Hospital of Sun Yat-sen University, YNCH Yunnan Cancer Hospital
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us